Favorable outcomes of tacrolimus compared with cyclosporine a for GVHD prophylaxis in HSCT for standard-risk hematological diseases

Annals of Hematology

Volumn 93, Issue 7, 2014, Pages 1215-1223

  Nasu, Ryo ^a   Nannya, Yasuhito ^a   Shinohara, Akihito ^a   Ichikawa, Motoshi ^a   Kurokawa, Mineo ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Calcineurin inhibitors; GVHD prophylaxis; Hematopoietic stem cell transplantation

Indexed keywords

CREATININE; CYCLOSPORIN A; METHOTREXATE; TACROLIMUS;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOPROPHYLAXIS; KIDNEY INJURY; LEUKEMIA REMISSION; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SURVIVAL RATE; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902653133     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2027-y     Document Type: Article

References (19)

1. Ball LM, Egeler RM, Party EPW (2008) Acute GvHD: pathogenesis and classification. Bone Marrow Transplant 41(Suppl 2):S58-S64. doi:10.1038/bmt. 2008.56 (Pubitemid 351864709)
2. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR (1998) Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92(7):2303-2314 (Pubitemid 28452971)
3. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, Przepiorka D, Davies S, Petersen FB, Bartels P, Buell D, Fitzsimmons W, Anasetti C, Storb R, Ratanatharathorn V (2000) Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96(6):2062-2068
4. Hiraoka A, Ohashi Y, Okamoto S, Moriyama Y, Nagao T, Kodera Y, Kanamaru A, Dohy H, Masaoka T, Japanese FKBMTSG (2001) Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 28(2):181-185. doi: 10.1038/sj.bmt.1703097 (Pubitemid 32725719)
5. Ruutu T, van Biezen A, Hertenstein B, Henseler A, Garderet L, Passweg J, Mohty M, Sureda A, Niederwieser D, Gratwohl A, de Witte T (2012) Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 47(11):1459-1464. doi:10.1038/bmt.2012.45
6. Alvarez JS, Sacristan JA, Alsar MJ (1992) Comparison of a monoclonal antibody fluorescent polarization immunoassay with monoclonal antibody radioimmunoassay for cyclosporin determination in whole blood. Ther Drug Monit 14(1):78-80
7. Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 94(446):496-509. doi:10.2307/2670170
8. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang MJ, Antin JH, Bolwell BJ, Bredeson C, Cahn JY, Cairo M, Gale RP, Gupta V, Lee SJ, Litzow M, Weisdorf DJ, Horowitz MM, Hahn T (2012) Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 119(1):296-307. doi:10.1182/blood- 2011-06-364265
9. Wingard JR, Nash RA, Przepiorka D, Klein JL, Weisdorf DJ, Fay JW, Zhu J,Maher RM, FitzsimmonsWE, Ratanatharathorn V (1998) Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transpl: J Am Soc Blood Marrow Transpl 4(3):157-163. doi:10.1053/bbmt.1998.v4.pm9923414 (Pubitemid 128538807)
10. RamR, Storer B,MielcarekM, SandmaierBM,Maloney DG,Martin PJ, Flowers ME, Chua BK, Rotta M, Storb R (2012) Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl: J Am Soc Blood Marrow Transpl 18(3):414-422. doi:10.1016/j.bbmt.2011.08.016
11. Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P, Bensinger W, Berenson R, Buckner CD, Clift R et al (1989) Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 73(6):1729-1734 (Pubitemid 19131924)
12. Morishima Y,Morishita Y, TanimotoM, Ohno R, Saito H, Horibe K, Hamajima N, Naito K, Yamada K, Yokomaku S et al (1989) Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group. Blood 74(6):2252-2256 (Pubitemid 19269137)
13. Storb R, Deeg HJ, Pepe M, Doney K, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Hansen J et al (1989) Graft-versus- host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. Br J Haematol 72(4):567-572 (Pubitemid 19220499)
14. Medd P, Monk I, Danby R, Malladi R, Clifford R, Ellis A, Roberts D, Hatton C, Vyas P, Littlewood T, Peniket A (2011) Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant. Int J Hemat 94(3):266-278. doi:10. 1007/s12185-011-0920-x
15. Kumar S, Wolf RC, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Litzow MR (2002) Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease. Bone Marrow Transplant 30(3):161-165. doi:10.1038/sj.bmt. 1703616
16. Miroux C, Morales O, Ghazal K, Othman SB, de Launoit Y, Pancre V, Conti F, Delhem N (2012) In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. Transplantation 94(2):123-131. doi:10.1097/TP.0b013e3182590d8f
17. Kanda Y, Kanda J, Atsuta Y,Maeda Y, Ichinohe T, Ohashi K, Fukuda T, Miyamura K, Iida H, Mori T, Iwato K, Eto T, Kawa K, Morita S, Morishima Y (2013) Impact of a single human leucocyte antigen (HLA) allele mismatch on the outcome of unrelated bone marrow transplantation over two time periods. A retrospective analysis of 3003 patients from the HLAWorking Group of the Japan Society for Blood and Marrow Transplantation. Br J Haematol. doi:10.1111/bjh. 12279
18. Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai HL, Bolanos- Meade J, Morris LE, Crilley PA, O'Donnell PV, Rossiter N, Huff CA, Brodsky RA, Matsui WH, Swinnen LJ, Borrello I, Powell JD, Ambinder RF, Jones RJ, Fuchs EJ (2010) Nonmyeloablative HLAhaploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transpl : J Am Soc Blood Marrow Transpl 16(4): 482-489. doi:10.1016/j.bbmt.2009.11.011
19. Wang Y, Liu DH, Liu KY, Xu LP, Zhang XH, Han W, Chen H, Chen YH, Wang FR, Wang JZ, Sun YQ, Huang XJ (2013) Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 119(5):978-985. doi: 10.1002/cncr.27761